Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pill could reduce blood transfusions for thalassemia patients

NCT ID NCT06302491

First seen Mar 02, 2026 · Last updated May 25, 2026 · Updated 13 times

Summary

This study tests an oral drug called AND017 in people with β-thalassemia, a blood disorder that often requires regular blood transfusions. The trial includes 64 adults who either need transfusions or do not. Participants receive AND017 or a placebo along with standard care. The goal is to see if the drug is safe and can raise hemoglobin levels, potentially reducing the need for transfusions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Β -THALASSEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangxi Medical University No.1 Affiliated Hospital

    RECRUITING

    Nanning, Guangxi, 530021, China

    Contact

  • Hainan General Hospital

    RECRUITING

    Haikou, Hainan, 570203, China

    Contact

  • Liuzhou People's Hospital

    RECRUITING

    Liuzhou, Guangxi, 545006, China

    Contact

  • Maoming People's Hospital

    RECRUITING

    Maoming, Guangdong, 525000, China

    Contact

  • Nanfang Hospital Southern Medical University

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, 510515, China

    Contact

Conditions

Explore the condition pages connected to this study.